IRIDEX Corporation enters its May 12 earnings window sitting at $1.03 — down 2% on the week — after one of the more dramatic short-selling episodes in its recent history.
The most telling detail this month is not where short interest is now, but where it has been. Short interest peaked around April 9 at roughly 308,000 shares — more than eight times the current level of 37,000 shares — before collapsing over the following three weeks. That spike coincided with a borrow cost run-up: cost to borrow hit 3.5% on April 14 and 3.2% on April 9, roughly six times its baseline. Both metrics have since retreated sharply. Borrowing cost is now 0.86%, and the lending market is wide open — availability has expanded dramatically from tightly constrained levels in mid-April back to near-normal conditions. The lending pool no longer reflects any urgency on the short side.
Options positioning tells a complementary story. The put/call ratio rose to 0.28 on April 29, up from a run of near-zero readings through mid-month, but remains well below its 20-day average of 0.34. Compared to late March — when the PCR was running above 0.75 — the current reading suggests the defensive hedging that dominated Q1 has largely unwound. The 52-week PCR high is 1.41, making today's positioning look close to neutral. The ORTEX short score has drifted lower over the past two weeks, from 28.1 on April 15 to 26.0 now, consistent with the broader short-position unwind. Overall positioning looks much less charged than it did a fortnight ago.
What makes the setup more nuanced is the CFO's persistent open-market buying. Romeo Dizon has bought shares on at least ten separate occasions between late January and early March, accumulating roughly 14,300 shares at prices ranging from $1.26 to $1.52 — all above the current $1.03 close. Total net insider buying over 90 days amounts to 82,680 shares, worth approximately $93,000. These are modest sums in absolute terms, but the frequency and consistency of the pattern — small lots, multiple dates, no offsetting sales — is notable for a company of this size. On the institutional side, Topcon Corporation holds 9.3% of shares with no reported change, and an unnamed holder added 439,000 shares as of April 1.
The earnings history adds an important caution. IRIDEX's most recent print, reported March 26, sent the stock down 25% on the day and 26% over the following five days. That is the scale of reaction the company has generated at recent results, and the May 12 event arrives with the stock already near multi-month lows. The company announced a distribution partnership with EyeProGPO earlier in April, offering its retinal laser devices at preferred pricing through a group purchasing organisation — a modest commercial catalyst that the market has not materially repriced.
The analyst price target on file is $2.75, last updated around March 27. At the current price that implies substantial upside on paper, but the target predates the post-earnings selloff and should be treated with caution until it is refreshed. What to watch into May 12 is whether the short-interest normalisation holds — or whether borrowing demand picks up again as the earnings date approaches.
See the live data behind this article on ORTEX.
Open IRIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
